The clinical community is keenly watching Synedica Retatrutide, a dual-action therapy targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Early research suggest it appears to offer meaningful gains in body fat reduction compared to available medications, perhaps representing a major development in the battle of